Skip to main content
main-content

19.01.2022 | Morbus Parkinson | Übersichten

Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen

verfasst von: Prof. Dr. Wolfgang H. Jost, Carsten Buhmann, Joseph Classen, Karla Eggert, Zacharias Kohl, Tiago Outeiro, Lars Tönges, Dirk Woitalla, Heinz Reichmann

Erschienen in: Der Nervenarzt

Einloggen, um Zugang zu erhalten

Zusammenfassung

Seit über 20 Jahren haben sich die COMT(Catechol-O-Methyltransferase)-Hemmer in der Therapie des Parkinson-Syndroms etabliert. Sie gelten als Mittel der Wahl bei motorischen Fluktuationen. Die verfügbaren Substanzen Entacapon, Opicapon und Tolcapon unterscheiden sich pharmakokinetisch hinsichtlich ihrer Halbwertszeiten, mit Folgen für die Einnahmefrequenz, hinsichtlich ihrer Indikationsvoraussetzungen und ihres Nebenwirkungsspektrums, darunter Diarrhöen und eine Gelbverfärbung des Urins. Viele Patienten mit motorischen Fluktuationen werden aktuell nicht mit COMT-Hemmern behandelt und erhalten deshalb vermutlich keine individuell optimale medikamentöse Therapie. Das vorliegende Manuskript fasst die Ergebnisse eines Arbeitstreffens mehrerer Parkinson-Experten zusammen, in dem der Stellenwert der COMT-Hemmer kritisch diskutiert wurde.
Zugang erhalten Sie mit:
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Antonini A, Ebersbach G, Rascol O et al (2020) Efficacy of opicapone in different treatment regimens in Parkinson’s disease patients with motor fluctuations. Park Relat Disord 79:e64–e65 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) Antonini A, Ebersbach G, Rascol O et al (2020) Efficacy of opicapone in different treatment regimens in Parkinson’s disease patients with motor fluctuations. Park Relat Disord 79:e64–e65 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
2.
Zurück zum Zitat Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30(1):80–89 PubMed Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30(1):80–89 PubMed
3.
Zurück zum Zitat Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560 PubMed Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560 PubMed
4.
Zurück zum Zitat Barichella M, Cereda E, Pezzoli G (2009) Major nutritional issues in the management of Parkinson’s disease. Mov Disord 24(13):1881–1892 PubMed Barichella M, Cereda E, Pezzoli G (2009) Major nutritional issues in the management of Parkinson’s disease. Mov Disord 24(13):1881–1892 PubMed
5.
Zurück zum Zitat Borovac JA (2016) Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med 89(1):37–47 PubMedPubMedCentral Borovac JA (2016) Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med 89(1):37–47 PubMedPubMedCentral
6.
Zurück zum Zitat Buhmann C, Bihler M, Emich K et al (2019) Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Park Relat Disord 62:51–56 Buhmann C, Bihler M, Emich K et al (2019) Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Park Relat Disord 62:51–56
7.
Zurück zum Zitat Campbell NR, Hasinoff BB (1991) Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 31(3):251–255 PubMedPubMedCentral Campbell NR, Hasinoff BB (1991) Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 31(3):251–255 PubMedPubMedCentral
8.
Zurück zum Zitat Carta M, Carlsson T, Muñoz A et al (2010) Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson’s disease. Mov Disord 1:174–179 Carta M, Carlsson T, Muñoz A et al (2010) Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson’s disease. Mov Disord 1:174–179
9.
Zurück zum Zitat Cattaneo C, La Ferla R, Bonizzoni E et al (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis 5(3):475–481 PubMedPubMedCentral Cattaneo C, La Ferla R, Bonizzoni E et al (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis 5(3):475–481 PubMedPubMedCentral
10.
Zurück zum Zitat Cenci MA, Lundblad A (2006) Post- versus presynaptic plasticity in L‑DOPA-induced dyskinesia. J Neurochem 99(2):381–392 PubMed Cenci MA, Lundblad A (2006) Post- versus presynaptic plasticity in L‑DOPA-induced dyskinesia. J Neurochem 99(2):381–392 PubMed
11.
Zurück zum Zitat Chaudhuri KR, Poewe W, Brooks D (2018) Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord 33:909–919 Chaudhuri KR, Poewe W, Brooks D (2018) Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord 33:909–919
12.
Zurück zum Zitat Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(10):2731–2742 PubMedPubMedCentral Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(10):2731–2742 PubMedPubMedCentral
13.
Zurück zum Zitat Corvol J, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189–e201 PubMedPubMedCentral Corvol J, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189–e201 PubMedPubMedCentral
15.
Zurück zum Zitat Ebersbach G, Rascol O, Ferreira JJ et al (2020) Efficacy/safety of opicapone in Parkinson’s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK‑I and II. Park Relat Disord 79:e63–e64 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) Ebersbach G, Rascol O, Ferreira JJ et al (2020) Efficacy/safety of opicapone in Parkinson’s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK‑I and II. Park Relat Disord 79:e63–e64 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
16.
Zurück zum Zitat Orion Pharma (2019) Fachinformation Comtess Orion Pharma (2019) Fachinformation Comtess
17.
Zurück zum Zitat Roche Pharma (2020) Fachinformation Madopar Roche Pharma (2020) Fachinformation Madopar
18.
Zurück zum Zitat Bial – Portela & Ca (2020) Fachinformation Ongentys Bial – Portela & Ca (2020) Fachinformation Ongentys
19.
Zurück zum Zitat MEDA Pharma (2020) Fachinformation Tasmar MEDA Pharma (2020) Fachinformation Tasmar
20.
Zurück zum Zitat Ferreira JJ, Lees A, Ebersbach G et al (2020) Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. Park Relat Disord 79:e61 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) Ferreira JJ, Lees A, Ebersbach G et al (2020) Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. Park Relat Disord 79:e61 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
21.
Zurück zum Zitat Ferreira JJ, Lees A, Rocha JF et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165 PubMed Ferreira JJ, Lees A, Rocha JF et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165 PubMed
22.
Zurück zum Zitat Ferreira JJ, Lees JA, Poewe W et al (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90(21):e1849–e1857 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) PubMed Ferreira JJ, Lees JA, Poewe W et al (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90(21):e1849–e1857 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) PubMed
23.
Zurück zum Zitat Fründt O, Veliqi E, Schönwald B et al (2020) Die Hamburger Parkinson-Tagesklinik: Ein neues Behandlungskonzept an der Grenze zwischen stationärer und ambulanter Versorgung. Fortschr Neurol Psychiatr 88(6):362–337 PubMed Fründt O, Veliqi E, Schönwald B et al (2020) Die Hamburger Parkinson-Tagesklinik: Ein neues Behandlungskonzept an der Grenze zwischen stationärer und ambulanter Versorgung. Fortschr Neurol Psychiatr 88(6):362–337 PubMed
24.
Zurück zum Zitat Gershanik OS (2015) Improving L‑dopa therapy: the development of enzyme inhibitors. Mov Disord 30:103–113 PubMed Gershanik OS (2015) Improving L‑dopa therapy: the development of enzyme inhibitors. Mov Disord 30:103–113 PubMed
25.
Zurück zum Zitat Grosset DG, Macphee GJA, Nairn M (2010) Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. BMJ 340:b5614 PubMed Grosset DG, Macphee GJA, Nairn M (2010) Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. BMJ 340:b5614 PubMed
26.
Zurück zum Zitat Heinzel S, Berg D, Binder S et al (2018) Do we need to rethink the epidemiology and healthcare utilization of Parkinson’s disease in Germany? Front Neurol 9:500 PubMedPubMedCentral Heinzel S, Berg D, Binder S et al (2018) Do we need to rethink the epidemiology and healthcare utilization of Parkinson’s disease in Germany? Front Neurol 9:500 PubMedPubMedCentral
28.
Zurück zum Zitat Jost WH (2010) Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci 289:69–73 PubMed Jost WH (2010) Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci 289:69–73 PubMed
29.
Zurück zum Zitat Klucken J, Barth J, Kugler P et al (2013) Unbiased and mobile gait analysis detects motor impairment in Parkinson’s disease. PLoS One 8(2):e56956 PubMedPubMedCentral Klucken J, Barth J, Kugler P et al (2013) Unbiased and mobile gait analysis detects motor impairment in Parkinson’s disease. PLoS One 8(2):e56956 PubMedPubMedCentral
30.
Zurück zum Zitat Kuoppamäki M, Korpela K, Marttila R et al (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65:443–455 PubMed Kuoppamäki M, Korpela K, Marttila R et al (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65:443–455 PubMed
31.
Zurück zum Zitat Lees A, Ferreira JJ, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197–206 PubMed Lees A, Ferreira JJ, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197–206 PubMed
32.
Zurück zum Zitat Lees A, Ferreira JJ, Poewe W et al (2020) Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations. Park Relat Disord 79:e57 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) Lees A, Ferreira JJ, Poewe W et al (2020) Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations. Park Relat Disord 79:e57 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
33.
Zurück zum Zitat LeWitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359(23):2468–2476 PubMed LeWitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359(23):2468–2476 PubMed
34.
Zurück zum Zitat Liebermann A, Vijay M (2004) Wearing-off of levodopa of greatest concern for PD patients. J Neurol 11(Suppl 2):109 Liebermann A, Vijay M (2004) Wearing-off of levodopa of greatest concern for PD patients. J Neurol 11(Suppl 2):109
35.
Zurück zum Zitat Lyte M (2010) Microbial endocrinology as a basis for improved L‑DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 74(5):895–897 PubMed Lyte M (2010) Microbial endocrinology as a basis for improved L‑DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 74(5):895–897 PubMed
36.
Zurück zum Zitat National Institute for Health and Care Excellence (2006) Parkinson’s disease in over 20s: diagnosis and management. Clinical guideline [CG35] National Institute for Health and Care Excellence (2006) Parkinson’s disease in over 20s: diagnosis and management. Clinical guideline [CG35]
37.
Zurück zum Zitat Nyholm D, Lewnder T, Gomes-Trolin C et al (2012) Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharm 35(3):111–117 Nyholm D, Lewnder T, Gomes-Trolin C et al (2012) Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharm 35(3):111–117
38.
Zurück zum Zitat Oertel WH, Berardelli A, Bloem BR et al (2011) Early (uncomplicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 217–236 Oertel WH, Berardelli A, Bloem BR et al (2011) Early (uncomplicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 217–236
39.
Zurück zum Zitat Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Trenkwalder C (2011) Late (complicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 237–267 Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Trenkwalder C (2011) Late (complicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 237–267
40.
Zurück zum Zitat Olanow CW, Kieburtz K, Rascol O et al (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071 Olanow CW, Kieburtz K, Rascol O et al (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071
41.
Zurück zum Zitat Reichmann H (2015) Therapie Tabellen Neurologie/Psychiatrie, 6. Aufl. Bd. 62. Westermayer, Pentenried, S 24 Reichmann H (2015) Therapie Tabellen Neurologie/Psychiatrie, 6. Aufl. Bd. 62. Westermayer, Pentenried, S 24
42.
Zurück zum Zitat Rekdal VM, Bess EN, Bisanz JE et al (2019) Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 364(6445):eaau6323 PubMedCentral Rekdal VM, Bess EN, Bisanz JE et al (2019) Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 364(6445):eaau6323 PubMedCentral
43.
Zurück zum Zitat Richter D, Bartig D, Jost WH et al (2019) Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna) 126(7):879–888 Richter D, Bartig D, Jost WH et al (2019) Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna) 126(7):879–888
44.
Zurück zum Zitat Rocha F, Almeida L, Falcão A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775 PubMedPubMedCentral Rocha F, Almeida L, Falcão A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775 PubMedPubMedCentral
45.
Zurück zum Zitat Rocha J, Falcão A, Santos A et al (2014) Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70:1059–1071 PubMed Rocha J, Falcão A, Santos A et al (2014) Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70:1059–1071 PubMed
46.
Zurück zum Zitat AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010 AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010
47.
Zurück zum Zitat AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010 (adaptiert) AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010 (adaptiert)
48.
Zurück zum Zitat Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis 3(3):255–269 PubMed Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis 3(3):255–269 PubMed
49.
Zurück zum Zitat Scott NW, Macleod AD, Counsell CE (2016) Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol 23(2):304–312 PubMed Scott NW, Macleod AD, Counsell CE (2016) Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol 23(2):304–312 PubMed
50.
Zurück zum Zitat Seemann P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189 Seemann P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189
52.
Zurück zum Zitat Stacy MA, Murphy JM, Greeley DR et al (2008) The sensitivity and specificity of the 9‑item wearing-off questionnaire. Park Relat Disord 14:205–212 Stacy MA, Murphy JM, Greeley DR et al (2008) The sensitivity and specificity of the 9‑item wearing-off questionnaire. Park Relat Disord 14:205–212
53.
Zurück zum Zitat Stocchi F, Coletti C, Bonassi S et al (2019) Early-morning OFF and levodopa dose failures in patients with Parkinson’s disease attending a routine clinical appointment using Time-to-ON Questionnaire. Eur J Neurol 26(5):821–826 PubMed Stocchi F, Coletti C, Bonassi S et al (2019) Early-morning OFF and levodopa dose failures in patients with Parkinson’s disease attending a routine clinical appointment using Time-to-ON Questionnaire. Eur J Neurol 26(5):821–826 PubMed
54.
Zurück zum Zitat Stocchi F, Antonini A, Barone P et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Park Relat Disord 20(2):204–211 Stocchi F, Antonini A, Barone P et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Park Relat Disord 20(2):204–211
55.
Zurück zum Zitat Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27 PubMed Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27 PubMed
56.
Zurück zum Zitat Sutton JP (2013) Dysphagia in Parkinson’s disease is responsive to levodopa. Park Relat Disord 19(3):282–284 Sutton JP (2013) Dysphagia in Parkinson’s disease is responsive to levodopa. Park Relat Disord 19(3):282–284
57.
Zurück zum Zitat Tambasco N, Romoli R, Calabresi P (2018) Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 16(8):1239–1252 PubMedPubMedCentral Tambasco N, Romoli R, Calabresi P (2018) Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 16(8):1239–1252 PubMedPubMedCentral
58.
Zurück zum Zitat Tönges L, Bartig D, Muhlack S et al (2019) Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015. Nervenarzt 90(2):167–174 PubMed Tönges L, Bartig D, Muhlack S et al (2019) Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015. Nervenarzt 90(2):167–174 PubMed
59.
Zurück zum Zitat Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med 380:315–324 PubMed Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med 380:315–324 PubMed
60.
Zurück zum Zitat Videnovic A, Poewe W, Lees A et al (2020) Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations. Mov Disord 35(Suppl 1):S486–S487 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September) Videnovic A, Poewe W, Lees A et al (2020) Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations. Mov Disord 35(Suppl 1):S486–S487 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
61.
Zurück zum Zitat Woodrow H, Horne MK, Fernando CV et al (2020) A blinded, controlled trial of objective measurement in Parkinson’s disease. npj Park Dis 6:35 Woodrow H, Horne MK, Fernando CV et al (2020) A blinded, controlled trial of objective measurement in Parkinson’s disease. npj Park Dis 6:35
62.
Zurück zum Zitat Zahoor I, Shafi A, Haq H et al (2018) Pharmacological treatment of Parkinson’s disease. In: Parkinson’s disease: pathogenesis and clinical aspects. Codon, Brisbane, S 129–144 (Chapter 7) Zahoor I, Shafi A, Haq H et al (2018) Pharmacological treatment of Parkinson’s disease. In: Parkinson’s disease: pathogenesis and clinical aspects. Codon, Brisbane, S 129–144 (Chapter 7)
Metadaten
Titel
Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen
verfasst von
Prof. Dr. Wolfgang H. Jost
Carsten Buhmann
Joseph Classen
Karla Eggert
Zacharias Kohl
Tiago Outeiro
Lars Tönges
Dirk Woitalla
Heinz Reichmann
Publikationsdatum
19.01.2022
Verlag
Springer Medizin
Schlagwort
Morbus Parkinson
Erschienen in
Der Nervenarzt
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-021-01237-3